SZSonia Zouaoui

Sonia Zouaoui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sonia Zouaoui has a total of 106 co-authors. Here are the top co-authors by number of shared publications:

  • Luc Taillandier

    Neuro-oncology Unit, Department of Neurology, University Hospital, Hôpital Central, Nancy, France

    6 shared publications
  • Amélie Darlix

    Department of Medical Oncology, Institut Régional du Cancer de Montpellier, University of Montpellier , Montpellier

    5 shared publications
  • Hugues Duffau

    Department of Medical Oncology, Institut Régional du Cancer de Montpellier - Val d’Aurelle, Montpellier, France

    5 shared publications
  • Luc Bauchet

    Department of Medical Oncology, Institut Régional du Cancer de Montpellier - Val d’Aurelle, Montpellier, France

    5 shared publications
  • Luc Bauchet

    Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, and INSERM 1191, IGF, Montpellier, France

    5 shared publications
  • Valérie Rigau

    10 Department of Pathology, University Hospital, Hôpital Gui de Chauliac, Montpellier, France

    4 shared publications

Latest Publications

  • Characteristics and management of hydrocephalus in adult patients with cerebellar glioblastoma: lessons from a French nationwide series of 118 cases

    by Thiébaud Picart, Chloé Dumot, David Meyronet, Johan Pallud, Philippe Metellus, Sonia Zouaoui, François Ducray, Isabelle Pelissou-Guyotat, Moncef Berhouma, Luc Bauchet, et al.

    The characteristics of hydrocephalus associated with cerebellar glioblastoma (cGB) remain poorly known. The objectives were to describe the occurence of hydrocephalus in a French nationwide series of adult patients with cGB, to identify the characteristics associated with hydrocephalus and to analyze the outcomes associated with the different surgical strategies, in order to propose practical guidelines. Consecutive cases of adult cGB patients prospectively recorded into the French Brain Tumor Database between 2003 and 2017 were screened. Diagnosis was confirmed by a centralized neuropathological review. Among 118 patients with cGB (mean age 55.9 years), 49 patients (41.5%) presented with pre-operative hydrocephalus. Thirteen patients (11.0%) developed acute (n=7) or delayed (n=6) hydrocephalus postoperatively. Compared to patients without hydrocephalus at admission, patients with hydrocephalus were younger (52.0 years vs 58.6 years, p=0.03) and underwent more frequently tumor resection (93.9% vs 73.9%, p=0.006). A total of 40 cerebrospinal-fluid diversion procedures were performed, including 18 endoscopic third ventriculostomies, 12 ventriculoperitoneal shunts and 10 external ventricular drains. The different cerebrospinal-fluid diversion options had comparable functional results and complication rates. Among the 89 patients surgically managed for cGB without prior cerebrospinal-fluid diversion, 7 (7.9%) were long-term shunt-dependant. Hydrocephalus is frequent in patients with cGB and has to be carefully managed in order not to interfere with adjuvant oncological treatments. In case of symptomatic hydrocephalus, a cerebrospinal-fluid diversion is mandatory, especially if surgical resection is not feasible. In case of asymptomatic hydrocephalus, a cerebrospinal-fluid diversion has to be discussed only if surgical resection is not feasible.


  • Management, functional outcomes and survival in a French multicentric series of 118 adult patients with cerebellar glioblastoma

    by French Brain Tumor DataBase, Thiébaud Picart, Club de Neuro-Oncologie of the Société Française de Neurochirurgie, David Meyronet, Johan Pallud, Chloé Dumot, Philippe Metellus, Sonia Zouaoui, Moncef Berhouma, François Ducray, et al.

    Purpose To analyze the outcomes and predictors in a large series of cerebellar glioblastomas in order to guide patient management. Methods The French brain tumor database and the Club de Neuro-Oncologie of the Société Française de Neurochirurgie retrospectively identified adult patients with cerebellar glioblastoma diagnosed between 2003 and 2017. Diagnosis was confirmed by a centralized neuropathological review. Results Data from 118 cerebellar glioblastoma patients were analyzed (mean age 55.9 years, 55.1% males). The clinical presentation associated raised intracranial pressure (50.8%), static cerebellar syndrome (68.6%), kinetic cerebellar syndrome (49.2%) and/or cranial nerve disorders (17.8%). Glioblastomas were hemispheric (55.9%), vermian (14.4%) or both (29.7%). Hydrocephalus was present in 49 patients (41.5%). Histologically, tumors corresponded either to IDH-wild-type or to K27-mutant glioblastomas. Surgery consisted of total (12.7%), subtotal (35.6%), partial resection (33.9%) or biopsy (17.8%). The postoperative Karnofsky performance status was improved, stable and worsened in 22.4%, 43.9% and 33.7% of patients, respectively. Progression-free and overall survivals reached 5.1 months and 9.1 months, respectively. Compared to other surgical strategies, total or subtotal resection improved the Karnofsky performance status (33.3% vs 12.5%, p < 0.001), prolonged progression-free and overall survivals (6.5 vs 4.3 months, p = 0.015 and 16.7 vs 6.2 months, p < 0.001, respectively) and had a comparable complication rate (40.4% vs 31.1%, p = 0.29). After total or subtotal resection, the functional outcomes were correlated with age (p = 0.004) and cerebellar hemispheric tumor location (p < 0.001) but not brainstem infiltration (p = 0.16). Conclusion In selected patients, maximal resection of cerebellar glioblastoma is associated with improved onco-functional outcomes, compared with less invasive procedures.


  • Recommandations pour le don d’organes issus de patients porteurs de tumeurs primitives cérébrales ou médullaires de la part de l’Association des neuro-oncologues d’expression française (ANOCEF) et le Club de neuro-oncologie de la Société française de neurochirurgie

    by Didier Frappaz, Emilie Le Rhun, Arnaud Dagain, Benoît Averland, Luc Bauchet, Alexandre Faure, Christian Guillaume, Sonia Zouaoui, François Provot, Florence Vachiery, et al.

  • Open Access

    A Probabilistic Atlas of Diffuse WHO Grade II Glioma Locations in the Brain

    by Sarah Parisot, Amélie Darlix, Cédric Baumann, Sonia Zouaoui, Yordanka Yordanova, Marie Blonski, Valérie Rigau, Stéphane Chemouny, Luc Taillandier, Luc Bauchet, et al.

    Diffuse WHO grade II gliomas are diffusively infiltrative brain tumors characterized by an unavoidable anaplastic transformation. Their management is strongly dependent on their location in the brain due to interactions with functional regions and potential differences in molecular biology. In this paper, we present the construction of a probabilistic atlas mapping the preferential locations of diffuse WHO grade II gliomas in the brain. This is carried out through a sparse graph whose nodes correspond to clusters of tumors clustered together based on their spatial proximity. The interest of such an atlas is illustrated via two applications. The first one correlates tumor location with the patient’s age via a statistical analysis, highlighting the interest of the atlas for studying the origins and behavior of the tumors. The second exploits the fact that the tumors have preferential locations for automatic segmentation. Through a coupled decomposed Markov Random Field model, the atlas guides the segmentation process, and characterizes which preferential location the tumor belongs to and consequently which behavior it could be associated to. Leave-one-out cross validation experiments on a large database highlight the robustness of the graph, and yield promising segmentation results.


  • Open Access

    Brain Tumor Epidemiology – A Hub within Multidisciplinary Neuro-oncology. Report on the 15th Brain Tumor Epidemiology Consortium (BTEC) Annual Meeting, Vienna, 2014

    by Adelheid Woehrer, Ching C. Lau, Daniela Prayer, Luc Bauchet, Myrna Rosenfeld, David Capper, Paul G. Fisher, Marcel Kool, Martin Müller, Johan M. Kros, et al.

    The Brain Tumor Epidemiology Consortium (BTEC) is an open scientific forum, which fosters the development of multi-center, international and inter-disciplinary collaborations. BTEC aims to develop a better understanding of the etiology, outcomes, and prevention of brain tumors (http://epi.grants.cancer.gov/btec/). The 15th annual Brain Tumor Epidemiology Consortium Meeting, hosted by the Austrian Societies of Neuropathology and Neuro-oncology, was held on September 9 - 11, 2014 in Vienna, Austria. The meeting focused on the central role of brain tumor epidemiology within multidisciplinary neuro-oncology. Knowledge of disease incidence, outcomes, as well as risk factors is fundamental to all fields involved in research and treatment of patients with brain tumors; thus, epidemiology constitutes an important link between disciplines, indeed the very hub. This was reflected by the scientific program, which included various sessions linking brain tumor epidemiology with clinical neuro-oncology, tissue-based research, and cancer registration. Renowned experts from Europe and the United States contributed their personal perspectives stimulating further group discussions. Several concrete action plans evolved for the group to move forward until next year's meeting, which will be held at the Mayo Clinic at Rochester, MN, USA.


  • Significant heterogeneity in the geographical distribution of diffuse grade II/III gliomas in France

    by Amélie Darlix, Sonia Zouaoui, Jean-Marc Virion, Valérie Rigau, Hélène Mathieu-Daudé, Marie Blonski, German Reyes-Botero, Faiza Bessaoud, Brigitte Trétarre, Fabienne Bauchet, et al.

    Diffuse WHO grade II and III gliomas (DGII/IIIG) are rare tumors, with few specific epidemiological studies. We aimed at describing the geographical distribution of a homogeneous series of histologically confirmed DGII/IIIG, over a four-year period (2006–2009), at a national level. The methodology is based on a multidisciplinary national network already established by the French Brain Tumor DataBase and data collected directly from every neuropathology department. Personal home addresses were collected for confirmed cases. For each region, the incidence of DGII/IIIG was analyzed and standardized on the age and sex distribution of the French population. The number of patients with newly diagnosed, histologically confirmed DGII/IIIG was 4,790. The overall crude rate was 19.4/106. To enable international comparisons, standardized rates were calculated as follows: 19.8/106, 18.8/106 and 16.0/106 (reference population, Europe, US and world, respectively). The geographical distribution by region showed significant differences, with higher incidence rates in Northeast and central parts of France. This work is the first studying the geographical distribution of a pure series of DGII/IIIG at a national level. It demonstrates significant heterogeneity in the distribution, and raises the question of the role of environmental and/or genetic risk(s) factor(s) for DGII/IIIG.


  • Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France

    by Sonia Zouaoui, Amélie Darlix, Pascale Fabbro-Peray, Hélène Mathieu-Daudé, Valérie Rigau, Michel Fabbro, Faiza Bessaoud, Luc Taillandier, François Ducray, Fabienne Bauchet, et al.

    The incidence of glioblastoma (GBM) has increased in patients aged 70 years or older, and will continue to grow. Elderly GBM patients have been excluded from most clinical trials; furthermore, optimal care management as well as benefit/risk ratio of GBM treatments are still being debated. This study describes oncological patterns of care, prognostic factors, and survival for patients ≥70 years in France. We identified patients over 70 with newly diagnosed and histologically confirmed GBM on data previously published by the French Brain Tumor DataBase. We included 265 patients. Neurological deficits and mental status disorders were the most frequent symptoms. The surgery consisted of resection (RS n = 95) or biopsy (B n = 170); 98 patients did not have subsequent oncological treatment. After surgery, first-line treatment consisted of radiotherapy (RT n = 76), chemotherapy (CT n = 52), and concomitant radiochemotherapy (CRC n = 39). The median age at diagnosis was 76, 74, and 73 years, respectively, for the untreated, B + RT and/or CT, RS ± RT and/or CT groups. Median survival (in days, 95 % CI) with these main strategies, when analyzed according to surgical groups, was: B-CT n = 41, 199[155–280]; B-CRC n = 21, 318[166–480]; B-RT n = 37, 149[130–214]; RS-CT n = 11, 245[211–na]; RS-CRC n = 18, 372[349–593]; RS-RT n = 39, 269[218–343]. This population study for elderly GBM patients is one of the most important in Europe, and could be considered as a historical cohort to compare future treatments. Moreover, we can hypothesize that elderly patients (versus patients <70 years) are undertreated. Karnofsky performance status seems to be the most relevant clinical predictive factor, and RS and CRC have a positive impact on survival for elderly GBM patients in the general population, at least when feasible.


    • 1 August 2013
      • Vol. 33  (8) , 3467-74

    Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma.

    by Amélie Darlix, Cédric Baumann, Véronique Lorgis, François Ghiringhelli, Marie Blonski, Bruno Chauffert, Sonia Zouaoui, Catherine Pinelli, Fabien Rech, Patrick Beauchesne, et al.

    Radiotherapy with concomitant and adjuvant temozolomide (six cycles) is the standard treatment after surgery in glioblastoma patients. Few studies have assessed the impact of additional cycles of temozolomide on survival. We conducted a bi-centric retrospective study comparing survival and toxicity according to the number of cycles of adjuvant temozolomide. Fifty-eight patients were included. All patients received radiotherapy with concomitant temozolomide. Thirty-eight patients received six cycles, while 20 received nine or more (median=14) cycles. The risk of recurrence was significantly higher in the group receiving six cycles compared to the other group. Prolonged treatment improved progression-free survival (p=0.03) and overall survival (p=0.01) in multivariate analysis without a significant increase in toxicity. Prolonged administration of temozolomide seems to improve progression-free and overall survival, without increased toxicity. Prospective studies in larger populations are needed to better-define the population to whom it can be proposed and its optimal duration.


  • Répartition géographique des cas incidents de gliomes de grade II et III OMS entre 2006 et 2009 en France métropolitaine

    by Amélie Darlix, Sonia Zouaoui, Jean-Marc Virion, Hélène Mathieu-Daudé, Hugues Duffau, Luc Taillandier, Luc Bauchet


  • Open Access

    Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older

    by Jacob G. Scott, Luc Bauchet, Tyler J. Fraum, Lakshmi Nayak, Anna R. Cooper, Samuel T. Chao, John H. Suh, Michael A. Vogelbaum, David M. Peereboom, Sonia Zouaoui, et al.

    BACKGROUND: The most‐used prognostic scheme for malignant gliomas included only patients aged 18 to 70 years. The purpose of this study was to develop a prognostic model for patients ≥70 years of age with newly diagnosed glioblastoma.METHODS: A total of 437 patients ≥70 years of age with newly diagnosed glioblastoma, pooled from 2 tertiary academic institutions, was identified for recursive partitioning analysis (RPA). The resulting prognostic model, based on the final pruned RPA tree, was validated using 265 glioblastoma patients ≥70 years of age from a data set independently compiled by a French consortium.RESULTS: RPA produced 9 terminal nodes, which were pruned to 4 prognostic subgroups with markedly different median survivals: subgroup I = patients P < .0001) median survivals for subgroups I (8.5 months), II (7.7 months), III (4.3 months), and IV (3.1 months).CONCLUSIONS: This model divides elderly glioblastoma patients into prognostic subgroups that can be easily implemented in both the patient care and the clinical trial settings. This purely clinical prognostic model serves as a backbone for the future incorporation of the increasing number of potential molecular prognostic markers. Cancer 2012. © 2012 American Cancer Society.